AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

29 May 25

Updated

14 Dec 25

Views

108

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

90.5%

7D

9.9%

Loading

1Y

90.5%

7D

9.9%

You can edit this narrative until Dec 15 2:05 PM. Then, changes will post as Updates.

Author's Valuation

US$35.447.6% undervalued

AnalystConsensusTarget Fair Value

Shared on 14 Dec 25

Fair value Increased 22%

AXGN: Market Development Progress Will Support Confidence In 2025 Outlook

Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.

Shared on 30 Nov 25

Fair value Increased 2.19%

AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead

Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.

Shared on 16 Nov 25

Fair value Increased 4.11%

AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook

Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.

Shared on 31 Oct 25

Fair value Increased 11%

Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.

AnalystConsensusTarget Fair Value

US$35.44

7.6% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

14.75%

Medical Equipment revenue growth rate

7.37%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.79%

Calculation

US$27.13m

Earnings '28

x

83.42x

PE Ratio '28

=

US$2.26b

Market Cap '28

US$2.26b

Market Cap '28

/

51.90m

No. shares '28

=

US$43.60

Share Price '28

US$43.60 Share Price '28

Discounted to 2025 @ 7.77% p.a.

=

US$34.83

Fair Value '25